| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/07/2004 | WO2004084927A2 Compositions for inducing of immunotolerance |
| 10/07/2004 | WO2004084920A2 Anti-inflammatory treatment based on strontium compounds |
| 10/07/2004 | WO2004084919A1 Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood |
| 10/07/2004 | WO2004084918A1 Antipruritic composition for external use on skin |
| 10/07/2004 | WO2004084917A1 Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugs |
| 10/07/2004 | WO2004084916A1 Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria |
| 10/07/2004 | WO2004084915A1 Use of n-acetyl-d-aminoglycosamine in treatment of non-specific inflammations related to physical or chemical factors |
| 10/07/2004 | WO2004084914A1 Use of n-acetyl-d-aminoglycosamine in treatment of organ lesions related to toxicosis of drugs or chemicals |
| 10/07/2004 | WO2004084913A1 Use of n-acetyl-d-aminoglycosamine in treatment of local lesions or systematic symptoms related to autoimmune reactions |
| 10/07/2004 | WO2004084912A1 Remedy for nerve damage |
| 10/07/2004 | WO2004084911A2 Use of roxithromycin or its derivatives for the modulation of immune responses |
| 10/07/2004 | WO2004084910A1 Compositions for treating angina |
| 10/07/2004 | WO2004084909A1 Formulations and methods of reducing toxicity of anti-infective agents |
| 10/07/2004 | WO2004084908A1 Prostaglandin compositions for the treatment of erectile dysfunction |
| 10/07/2004 | WO2004084907A2 ACTIVATION SPECIFIC INHIBITORS OF NF-kB AND METHOD OF TREATING INFLAMMATORY PROCESSES IN CARDIO-VASCULAR DISEASES |
| 10/07/2004 | WO2004084906A1 Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species |
| 10/07/2004 | WO2004084905A2 Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
| 10/07/2004 | WO2004084904A1 A method of treating liver disease |
| 10/07/2004 | WO2004084903A1 Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis |
| 10/07/2004 | WO2004084902A1 Use of a trioxopyrimidine for the treatment of chronic wounds |
| 10/07/2004 | WO2004084901A1 Methods for treating or preventing an inflammatory or metabolic condition by inhibiting jnk |
| 10/07/2004 | WO2004084900A1 Topical formulation and use of buspirone |
| 10/07/2004 | WO2004084899A1 Medicinal composition containing pyrrolopyridazine compound |
| 10/07/2004 | WO2004084898A1 2-phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
| 10/07/2004 | WO2004084897A1 Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| 10/07/2004 | WO2004084895A2 Modulation of cell death |
| 10/07/2004 | WO2004084894A1 Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases |
| 10/07/2004 | WO2004084893A1 Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53 |
| 10/07/2004 | WO2004084892A1 Use of ritonavir for the treatment of unconjugated hyperbilirubinemia |
| 10/07/2004 | WO2004084891A1 Methods for treating inflammatory conditions or inhibiting jnk |
| 10/07/2004 | WO2004084889A1 Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
| 10/07/2004 | WO2004084886A1 THE USE OF BLOCKERS FOR THE LONG-TERM INHIBITION OF Na+-K+-ATPase AND/OR Na+/H+ EXCHANGE ACTIVITIES FOR THE PREPARATION OF A MEDICAMENT FOR THE INTESTINAL THERAPY |
| 10/07/2004 | WO2004084885A1 Compositions for the improvement of obesity |
| 10/07/2004 | WO2004084884A1 Use of tanshinone derivates as cholinesterase inhibitors in treating related diseases |
| 10/07/2004 | WO2004084883A1 Complexes of isotretinoin with natural beta or gamma-cyclodextrin |
| 10/07/2004 | WO2004084882A1 Use of arachidonic acid for normalization of infradian rhythm |
| 10/07/2004 | WO2004084881A1 METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS |
| 10/07/2004 | WO2004084880A1 METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
| 10/07/2004 | WO2004084879A1 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| 10/07/2004 | WO2004084878A1 Compositions and methods for treatment of premature ejaculation |
| 10/07/2004 | WO2004084877A1 Composition for ophthalmic use |
| 10/07/2004 | WO2004084876A2 Use of compounds for the prevention of drug-induced cell toxicity |
| 10/07/2004 | WO2004084875A1 Use of pinitol or chiroinositol for protecting the liver |
| 10/07/2004 | WO2004084874A2 Mtp inhibitors for inhibiting inflammation |
| 10/07/2004 | WO2004084873A1 Oral delivery system comprising an antibacterial and an anti-inflammatory agent |
| 10/07/2004 | WO2004084868A1 Morphine controlled release system |
| 10/07/2004 | WO2004084867A1 The colon-targeted pharmaceutical compositions of gastrointestinal motility drugs and their use |
| 10/07/2004 | WO2004084865A1 Formulations comprising an active ingredient and cocoa powder and use thereof |
| 10/07/2004 | WO2004084864A1 Formulations comprising tolterodine and cocoa powder and use thereof |
| 10/07/2004 | WO2004084861A2 Angiogenesis promotion by prostaglandin compositions and methods |
| 10/07/2004 | WO2004084855A1 Keratolytic composition with anti-allergic anti-inflammatory properties |
| 10/07/2004 | WO2004084843A2 Inhibitors of cathepsin s |
| 10/07/2004 | WO2004084835A2 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
| 10/07/2004 | WO2004084832A2 Measurement of estrogen activity in plants and a composition therefrom |
| 10/07/2004 | WO2004084831A2 Optimized expression of hpv 31 l1 in yeast |
| 10/07/2004 | WO2004084829A2 Esterified fatty acid composition |
| 10/07/2004 | WO2004084827A2 Reduction of zinc-induced neurotoxic injury by blockade of nitric oxide synthesis |
| 10/07/2004 | WO2004084826A2 Antifungal nail coat and method of use |
| 10/07/2004 | WO2004084824A2 Biaryl substituted 6-membered heterocyles as sodium channel blockers |
| 10/07/2004 | WO2004084818A2 Measurement of estrogen activity in plants and a composition therefrom |
| 10/07/2004 | WO2004084817A2 Siderophore conjugates of photoactive dyes for photodynamic therapy |
| 10/07/2004 | WO2004084816A2 IMPROVED CD4-IgG2 FORMULATIONS |
| 10/07/2004 | WO2004084814A2 High viscosity xanthan polymer preparations |
| 10/07/2004 | WO2004084809A2 Neuroprotective macrocylic compounds and methods for their use |
| 10/07/2004 | WO2004084801A2 Treatments for leishmaniasis |
| 10/07/2004 | WO2004084799A2 Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof |
| 10/07/2004 | WO2004084796A2 Compounds for the treatment of flaviviridae infections |
| 10/07/2004 | WO2004084769A2 Stents |
| 10/07/2004 | WO2004084703A2 Temporary embolization using inverse thermosensitive polymers |
| 10/07/2004 | WO2004084655A1 Comestibles containing isomaltulose and trehalose for sustained carbohydrate energy release and reduced glycemic/insulinemic responses, and for preserving osmolality |
| 10/07/2004 | WO2004084645A2 Use of allicin as preservative, as disinfectant, as antimicrobial or as biocidal agent |
| 10/07/2004 | WO2004075919A3 Compounds for protein stabilization and methods for their use |
| 10/07/2004 | WO2004074276B1 BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| 10/07/2004 | WO2004069198A3 Sugar-free oral transmucosal solid dosage forms and uses thereof |
| 10/07/2004 | WO2004069141A3 Transdermal granisetron |
| 10/07/2004 | WO2004067027A9 Osteogenic composition |
| 10/07/2004 | WO2004066924A3 Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| 10/07/2004 | WO2004066913A3 Solid mosapride preparation |
| 10/07/2004 | WO2004062729A8 Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 10/07/2004 | WO2004062666A3 Use of rho-kinase inhibitorrs for treatment of benign prostatic hyperplasia |
| 10/07/2004 | WO2004062561A3 Pharmaceutical compositions comprising fentanyl for intranasal delivery |
| 10/07/2004 | WO2004060362B1 COMPOSITIONS AND METHODS FOR INHIBITING TGF-β |
| 10/07/2004 | WO2004060353A9 Solid dispersions comprising a hygroscopic and/or deliquescent drug |
| 10/07/2004 | WO2004060345A3 Dispersible pharmaceutical compositions |
| 10/07/2004 | WO2004058163A3 Pharmaceutical compositions and method of treating parkinson's disease |
| 10/07/2004 | WO2004054514A3 C-6 modified indazolylpyrrolotriazines |
| 10/07/2004 | WO2004053107A3 Methods for treating diabetes |
| 10/07/2004 | WO2004047738A3 Arylcyclopropylcarboxylic amides as potassium channel openers |
| 10/07/2004 | WO2004047729B1 Composition for the prevention and treatment of inflammation of the ear |
| 10/07/2004 | WO2004045518A3 Open chain prolyl urea-related modulators of androgen receptor function |
| 10/07/2004 | WO2004041243A3 Stable amorphous celecoxib composite and process therefor |
| 10/07/2004 | WO2004041176A3 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus |
| 10/07/2004 | WO2004041164A3 Kinase inhibitors |
| 10/07/2004 | WO2004039327A3 Use of equol for treating androgen mediated diseases |
| 10/07/2004 | WO2004039322A3 Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
| 10/07/2004 | WO2004037165A3 Nitric oxide and its biomedical significance |
| 10/07/2004 | WO2004034980A3 Treatment for traumatic synovitis and damaged articular cartilage |
| 10/07/2004 | WO2004032709A3 Inhibition of src for treatment of reperfusion injury related to revascularization |
| 10/07/2004 | WO2004026829A3 Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors |
| 10/07/2004 | WO2004026255A3 Compositions and methods for preventing infection |